iShares Biotechnology ETF (NQ:IBB)

208.95 +1.21 (+0.58%)

Delayed Quote Updated: 10:08 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

28 29 Next >

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January ↗

January 30, 2023

Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.

Via Talk Markets

What Are The Equities Market’s Warning Signs? ↗

January 30, 2023

The 52-week New High / New Low ratio for the Nasdaq Composite has actually begun to deteriorate, a clear Risk-Off indication for the short term.

Via Talk Markets

Inflation, What Inflation? ↗

January 29, 2023

We typically have a song or two in our heads. After all, watching ticks is musical and has a lot of different beats. And typically, those songs turn into parodies.

Via Talk Markets

Global Stocks: Breaking Out? ↗

January 28, 2023

The S&P 500 is attempting to clear what has been an insurmountable trendline dating back to January 2022.

Via Talk Markets

The 3 Best Biotech Stocks Under $1 to Buy for January ↗

January 26, 2023

Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich.

Via InvestorPlace

Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug ↗

January 06, 2023

Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.

Via Benzinga

SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday ↗

January 06, 2023

Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to

Via Benzinga

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro ↗

December 19, 2022

The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.

Via Talk Markets

Tarsus Added to NASDAQ Biotechnology Index

December 16, 2022

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Small Caps Vs Large Caps: Who Is Leading? ↗

December 07, 2022

Clearly, large-cap stocks have been leading with the Dow Jones down the last year to date, but even though the selling pressure has been constant, trading volume has been anemic.

Via Talk Markets

Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades' ↗

December 05, 2022

The iShares Biotechnology ETF (NASDAQ: IBB), which includes several large cap biotechs, has recently narrowed its year-to-date loss to aroun

Via Benzinga

BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

December 02, 2022

The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs...

Via TheNewswire.com

Topics Stocks

BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients

December 02, 2022

By Faith Ashmore, Benzinga

Via News Direct

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients ↗

December 01, 2022

The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption.

Via Benzinga

Will The Dow Jones Continue Higher? Will The Nasdaq Follow? ↗

November 29, 2022

It's been a volatile few weeks in the markets, and it can be hard to tell if we're currently in a risk-on or risk-off environment.

Via Talk Markets

Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead ↗

November 28, 2022

Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.

Via Talk Markets

Market Currents: Why Pick Stocks? ↗

November 28, 2022

Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...

Via Talk Markets

Look Who’s Leading Now ↗

November 01, 2022

All indexes are near either their 50 or 200 DMA’s as we head into the Fed’s announcement tomorrow.

Via Talk Markets

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Can Biotech Stocks Continue Rallying In This Bear Market? ↗

October 31, 2022

Via Talk Markets

October Was Not So Scary After All - Things To Keep A Watch Out For ↗

October 31, 2022

Via Talk Markets

These 4 ETFs Feature on CNBC's 'Final Trades' ↗

October 27, 2022

On CNBC’s “Halftime Report Final Trades,” JPMorgan Private Bank’s Anastasia Amoroso chose iShares iBoxx $ High Yield Corporate Bond ETF (NYSE: HYG), saying that she wanted &ldq

Via Benzinga

Russell 2000: How Money Is Made And Lost In Small Caps ↗

October 19, 2022

IWM is in a bearish phase along with the other indices, but recent price action has shown relative strength.

Via Talk Markets

The Four Indices: Where Each Are In A 4-Year Cycle ↗

October 19, 2022

In the aftermath of last week’s market plunge and continued rally since, it is worth noting that the 200-week historic weekly support levels held for the SPY and the DIA, both of which were in danger...

Via Talk Markets

Steady As She Goes With Healthcare Stocks ↗

October 17, 2022

Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports.

Via Talk Markets

Precarious Action In The Bonds And Stock Market ↗

October 16, 2022

Analysts and researchers claimed that double thrusts in the market have always preceded positive returns. Always, huh?

Via Talk Markets

Taking The Temperature Of The Major Sector ETFs ↗

October 12, 2022

One of the most important first steps towards trading success is to tilt your trading towards trending sectors that display strength and avoid market weakness.

Via Talk Markets

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.